Family of high affinity antibodies for cancer treatment
CA 2000913 C · Owner: Mezes, Peter · Inventors: Rixon, Mark; Mezes, Peter; Gourlie, Brian
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention concerns a family of chimeric antibodies with high affinities to a high molecular weight, tumor-associated sialylated glycoprotein antigen (TAG72) of human origin. These antibodies have (1) high affinity animal V H and V L sequences which mediate TAG-72 binding and (2) human C H and C L regions. They are thought to produce significantly fewer side-effects when administered to human patients by virtue of their human C H and C L antibody domains. The nucleotide and amino acid sequences of V H.alpha.TAG V H, CC46 V H CC49H, CC83 V H, and CC92 V H, and CC49L CC83 V L, and CC92 V L idiotype, sequences are disclosed as well as in vivo methods of, treatment and diagnostic assay …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 18, 1989 and granted February 16, 1999. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended October 18, 2009.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 18, 2011.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.